WELCOME TO Million Health Pharmaceuticals

LediHep tablets are used to treat chronic hepatitis C viral infection in both adults & pediatric patient with the age of 12 years or older, or weighing of at least 35kg. LediHep tablets should be used in; Hepatitis C associated with genotype I, IV, V, or VI with compensated cirrhosis or without cirrhosis. HCV infection related to genotype I infection with decompensated cirrhosis by concomitant use of ribavirin. In liver transplanted patients, HCV associated to genotype I or IV without cirrhosis or with compensated cirrhosis by combining with ribavirin. LediHep tablets are used in pediatric patients with HCV infection caused by genotype I, IV, V or VI without cirrhosis or with compensated cirrhosis.

The common adverse produced during or after completion of therapy are; Exposure of HBV rejuvenation in HCV/HBV co infected patients.


Ledipasvir is a strong prohibitor of chronic hepatitis C viral associating non structural 5A protein which is a viral phosphoprotein. The vital role of ledipasvir in anti-viral activity mechanism; Inhibition of; Replication Assembly Secretion The mechanism of sofosbuvir involved in anti-viral activity is; Sofosbuvir is prohibitor of nucleotide analogue of hepatitis C viral infection related to non structural 5B polymerase. This enzyme is responsible for intervene the HCV RNA multiplication. The active form of sofosbuvir is in triphosphate form, which involved decreasing the natural cellular uridine nucleotide & is integrated by HCV RNA polymerase into the extended RNA primer strand, which is concluded in viral chain elimination.


The pharmacokinetic property of LediHep is; The median plasma concentration time of ledipasvir is 4 to 4.5 hours; sofosbuvir is absorbed rapidly and reaches median plasma concentration time is 0.8 to 1 hour; metabolite GS-331007 occurs between 3.5 to 4 hours.

Food should not cause any variation in pharmacokinetic property of LediHep . LediHep should be taken either with food or without food.

LediHep is widely distributed in body, the human plasma protein binding capacity of ledipasvir is around >99.8%; sofosbuvir is between 61 to 65%. LediHep metabolism is mostly occurred in liver, ledipasvir metabolism is occurred by CYP1A2, 2C8, 2C9, 2C19, 2D6 & 3A4.

The metabolism of sofosbuvir is majorly occurs hepatically and leads by cathepsin A or carboxyl esterase 1. LediHep is excreted through feces & urine. Ledipasvir dose are eliminated via urine by 87%.

Sofosbuvir is eliminated by 80% via urine, 14% via feces & 3.5% via exhaled air. Ledipasvir half life period is 47 hours; Sofosbuvir & GS-331007 Half life period is 0.5 to & 27 hours respectively.


Brand : LediHep
Ingredients : Ledipasvir + Sofosbuvir
Strength : 90mg 400mg
Manufactured : Zydus Heptiza
Package : 28 tablets


Generally LediHep tablet dosage recommended for adults & pediatric age 12 years to <18 years; The prescribed dose of LediHep is one tablet should be administered as a single dose by administering with or without food. Recommendation of dosage of LediHep in various conditions; including HIV-1 co infected patients Patient without cirrhosis: (adult or pediatric of 12 years of age or older with genotype I, IV, V or VI Chronic HCV) The advised dose of LediHep for this condition is one tablet should be administered orally as a single dose for 12 weeks

Genotype I

Without cirrhosis or compensated cirrhosis: LediHep should be used alone as a single dose followed for 12 weeks Therapy experienced without cirrhosis: LediHep should be used as a single agent for once a day for 12 weeks Therapy experienced with compensated cirrhosis: LediHep tablet should be used for 24 weeks In decompensated cirrhosis: LediHep with ribavirin should be used followed for 12 weeks

Genotype I to IV

In liver transplantation patients with compensated cirrhosis or without cirrhosis: LediHep tablet should be combined with ribavirin for 12 weeks.

Genotype IV, V or VI

Without cirrhosis or with compensated cirrhosis patients: LediHep tablets should be administered alone for 12 weeks The dose of ribavirin should be calculated on the basis of body weight; <75kg: 1000mg; ≥75kg: 1200mg Ribavirin should be administered with food. LediHep should be administered with or without food.

Genotype I

Without cirrhosis or with compensated cirrhosis: LediHep should be administered orally afor 12 weeks. Therapy experienced without cirrhosis: LediHep should be administered orally for 12 weeks. Therapy experienced compensated cirrhosis: LediHep tablet should be administered orally for 12 weeks.

Genotype IV, V or VI

Therapy naïve or experienced without cirrhosis or with compensated cirrhosis: LediHep tablet should be administered orally for 12 weeks.

Renal impairment patients

LediHep dosage adjustment should not be allowed in severe renal damaged condition. Due to greater exposure of sofosbuvir metabolite causes final stage of renal disease (ERSD).


Elevation of bilirubin Elevation of lipase Elevation of creatine kinase Severe bradycardia HBV reactivation Chest pain Dizziness Trouble in breathing Fatigue Headache Nausea Diarrhea Insomnia

The patients who are co infected with HBV/HCV will cause Exposure of hepatitis B virus reoccurrence

This fatal case occurs in patient who are undergoing anti-viral treatment (during or completion of therapy) or fail to take the anti-hepatitis B drugs. To avoid this problem patient should be examine the HBsAg & anti-HBC counts before start the therapy. Monitor the hepatic function test frequently. Initiation of proper anti-hepatitis B viral therapy occurs.

Severe bradycardia

This severe condition should be produced by concomitant use of LediHep with amiodarone. Overcome the problem by stop this combinational treatment. Counsel the patient before starting the treatment about the risk due to this combination. Check ECG periodically. Initiate supportive measures.

Exposure of adverse effect due to combination of LediHep with P-gp inducers

This combination causes loss of therapeutic effect of LediHep . To avoid the problem, stop the combination.

Exposure of adverse effects associated with ribavirin

LediHep ribavirin combination should be avoided. Ribavirin causes fetal damage and concludes as fetal death.



Ledipasvir is a component of LediHep , which is involved in inhibition of P-gp or BCRP drug transporters. This combination causes elevation of intestinal absorption of these substrates. LediHep with P-gp strong inducers, causes decreasing the plasma concentration of component of LediHep . Finally leads to loss of effectiveness of LediHep . Variation in INR values occurs due to combination of LediHep with warfarin. LediHep with gastric regulators drug causes decreasing the sofosbuvir & ledipasvir concentration. Avoid this co administration.

LediHep with anti-arrhythmic drugs causes increasing the concentration of these drugs. LediHep with anti-convulsants or anti-mycobacterials causes decreasing the concentration of both the component of LediHep . LediHep with anti-retroviral drugs causes increasing the concentration of these retroviral medicines. LediHep with herbal supplements like st Johns wort leads to produce the elevation of concentration of st Johns wort and reduced the effect of concentration of LediHep and causes loss of therapeutic effect of LediHep . LediHep with lipid lowering agents causes increasing effect of concentration of these drugs.

abdominal pain
abdominal pain
concluded as death
concluded as death
dark urine
dark urine
flu like syndrome
flu like syndrome
loss of apetite
loss of apetite
loss of weight
loss of weight

Quick Contact

Prescription upload

Top Products


Millionpharma.com , a fully licensed and regulated pharmacy medicine, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.

Millionpharma.com will not dispense any prescription medication without a valid prescription from a licensed physician.

If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.

The drug information provided in the Millionpharma.com is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.

Millionpharma.com requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from Millionpharma.com

At Millionpharma.com , a Caregiver can order prescription medicines on your behalf.


This information should not be used to decide whether or not to take this Product or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this Product . It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this product. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this product.